Treatment & Research

Current approaches to managing Alzheimer's disease and promising research directions.

Management

Current Treatment Approaches

While there is no cure for Alzheimer's disease, several approaches can help manage symptoms and improve quality of life.

Medications

Several medications are approved to treat symptoms of Alzheimer's disease:

Cholinesterase Inhibitors

These drugs (donepezil, rivastigmine, galantamine) prevent the breakdown of acetylcholine, a chemical messenger important for memory and learning.

Memantine

Regulates the activity of glutamate, another chemical messenger involved in learning and memory.

Aducanumab (Aduhelm)

A newer medication that targets beta-amyloid plaques in the brain, potentially slowing cognitive decline in early stages.

Combination Medications

Some medications combine different approaches for potentially better results.

Non-Drug Approaches

Several non-pharmacological approaches can help manage symptoms and improve quality of life:

Cognitive Stimulation

Activities that stimulate thinking, concentration, and memory, such as puzzles, games, and art therapy.

Physical Exercise

Regular physical activity can help maintain physical function and may improve mood and sleep quality.

Occupational Therapy

Helps develop strategies to maintain independence in daily activities for as long as possible.

Environmental Modifications

Creating a safe, structured environment that reduces confusion and supports function.

Managing Behavioral Symptoms

Behavioral and psychological symptoms can be challenging. Approaches include:

Identifying Triggers

Understanding what causes agitation, aggression, or other behaviors can help prevent or minimize them.

Creating Routine

Consistent daily schedules can reduce confusion and anxiety.

Validation Therapy

Acknowledging the person's feelings and perceptions rather than correcting or contradicting them.

Medications

In some cases, medications may be prescribed to manage severe behavioral symptoms, though they carry risks.

Support for Caregivers

Caring for someone with Alzheimer's is demanding. Support includes:

Education

Learning about the disease and effective caregiving strategies.

Support Groups

Connecting with others facing similar challenges for emotional support and practical advice.

Respite Care

Temporary relief from caregiving responsibilities to prevent burnout.

Counseling

Professional support to address the emotional impact of caregiving.

History

Timeline of Alzheimer's Treatments

The evolution of treatments for Alzheimer's disease over time.

1

1906

Dr. Alois Alzheimer identifies the disease after examining the brain of a woman who had died of an unusual mental illness.

2

1970s

Alzheimer's disease is recognized as the most common cause of dementia. Research begins to focus on the cholinergic system in the brain.

3

1993

Tacrine (Cognex) becomes the first FDA-approved drug specifically for Alzheimer's disease, though it's rarely used today due to side effects.

4

1996-2000

Second-generation cholinesterase inhibitors are approved: donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne).

5

2003

Memantine (Namenda), which works through a different mechanism than cholinesterase inhibitors, is approved for moderate to severe Alzheimer's.

6

2014

Namzaric, a combination of donepezil and memantine, is approved for moderate to severe Alzheimer's disease.

7

2021

Aducanumab (Aduhelm) becomes the first FDA-approved therapy to address the underlying biology of Alzheimer's disease by targeting beta-amyloid plaques.

8

Future

Numerous treatments targeting various aspects of Alzheimer's pathology are in development, including additional anti-amyloid therapies, tau-targeting treatments, and neuroprotective approaches.

Innovation

Current Research Directions

Scientists are exploring multiple approaches to better understand, treat, and potentially prevent Alzheimer's disease.

Microscopic image of amyloid plaques in brain tissue

Amyloid-Targeting Therapies

Beta-amyloid plaques are a hallmark of Alzheimer's disease. Researchers are developing several approaches to target these toxic protein deposits:

  • Monoclonal Antibodies: These laboratory-produced molecules can bind to specific targets like amyloid plaques. Examples include aducanumab, lecanemab, and donanemab.
  • Beta-secretase (BACE) Inhibitors: These drugs aim to block an enzyme involved in the production of beta-amyloid.
  • Gamma-secretase Modulators: These compounds aim to alter the activity of another enzyme involved in amyloid production.
  • Anti-aggregation Agents: These compounds aim to prevent beta-amyloid from clumping together to form plaques.

While some amyloid-targeting therapies have shown promise in clinical trials, the relationship between amyloid clearance and cognitive improvement remains complex and is an active area of research.

Participation

Clinical Trials

Clinical trials are essential for developing new treatments. Learn about the process and how to participate.

Why Participate in Clinical Trials?

  • Access to cutting-edge treatments before they're widely available
  • Regular monitoring by healthcare professionals
  • Contributing to scientific knowledge and helping future patients
  • Playing an active role in your own healthcare

Types of Clinical Trials

  • Treatment trials: Test new treatments or new combinations of treatments
  • Prevention trials: Look for ways to prevent disease in people who have never had it or to prevent it from returning
  • Diagnostic trials: Find better tests or procedures for diagnosing a disease
  • Screening trials: Test the best way to detect certain diseases or health conditions
  • Quality of life trials: Explore ways to improve comfort and quality of life for individuals with chronic illness

Clinical Trial Phases

Phase I

Tests a new drug or treatment in a small group (20-80 people) to evaluate its safety, determine a safe dosage range, and identify side effects.

Phase II

The drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.

Phase III

The drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow it to be used safely.

Phase IV

Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Find a Clinical Trial

If you're interested in participating in a clinical trial for Alzheimer's disease, several resources can help you find appropriate studies:

Active Alzheimer's Clinical Trials by Phase

Note: This chart represents approximate numbers and is for illustrative purposes only. For current information, visit ClinicalTrials.gov.

Want to learn more? Explore prevention strategies and caregiving tips.

Prevention Strategies
Find Resources